HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab.

AuthorsKayo Jin, Yasushi Matsuzaki, Eijiro Akasaka, Hajime Nakano, Daisuke Sawamura
JournalThe Journal of dermatology (J Dermatol) Vol. 46 Issue 3 Pg. e108-e109 (Mar 2019) ISSN: 1346-8138 [Electronic] England
PMID30192400 (Publication Type: Case Reports, Letter)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • Cyclosporine
  • secukinumab
  • Adalimumab
Topics
  • Adalimumab (therapeutic use)
  • Administration, Oral
  • Antibodies, Monoclonal (adverse effects)
  • Antibodies, Monoclonal, Humanized
  • Arthritis, Psoriatic (drug therapy)
  • Cyclosporine (therapeutic use)
  • Dermatologic Agents (therapeutic use)
  • Drug Substitution (adverse effects)
  • Female
  • Humans
  • Middle Aged
  • Pyoderma Gangrenosum (chemically induced, diagnosis, drug therapy, pathology)
  • Skin (drug effects, pathology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: